Sabestomig
Based on 1 Customer Validation
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.33%
- CAS. Nr.: 2648346-74-9
- Molecular Weight:146.032 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
PDCD1 & HAVCR2
Sabestomig enhances efferocytosis and tumor antigen cross-presentation in human monocyte-derived dendritic cells[1].
Sabestomig increases anti-tumor T-cell responses in co-cultures of PD-1+ TIM-3+ virally-reactive human T-cells and viral peptide-expressing tumor cell lines, with greater activity than anti-PD-1 or a PS-blocking PD-1/TIM-3 bispecific antibody[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-lambda-kappa
ELISA, FACS, Functional assay
-
Immobilized PD-1 Protein, Human (HEK293, His, HY-P7396) can bind Sabestomig. The EC50 for this effect is 23.46 ng/mL. -
Immobilized TIM-3/HAVCR2 Protein, Human (HEK293, His HY-P70482) can bind Sabestomig. The EC50 for this effect is 32.83 ng/mL.
Chemical Information
-
CAS. Nr. 2648346-74-9
-
Appearance Liquid
-
Molecular Weight 146.032 kDa
-
Color Colorless to light yellow
-
Synonyms
AZD7789
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Sabestomig Related Classifications
HY-P990716 Related Classifications
Powered by Bioz
- Sabestomig
- 2648346-74-9
- AZD7789
- AZD 7789
- AZD-7789
- PD-1/PD-L1
- Tim3
- human monocyte-derived dendritic cells
- non-small cell lung cancer
- TIM-3
- phosphatidylserine-binding cleft
- PD-1+ TIM-3+ virally-reactive human T-cells
- IL-2
- PD-1
- Jurkat T-cells
- classical Hodgkin lymphoma
- viral peptide-expressing tumor cell lines
- Inhibitor
- inhibitor
- inhibit